Jpmorgan Chase & CO Longboard Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 505,174 shares of LBPH stock, worth $9.53 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
505,174
Previous 534,716
5.52%
Holding current value
$9.53 Million
Previous $3.22 Million
238.43%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding LBPH
# of Institutions
106Shares Held
30MCall Options Held
16.3KPut Options Held
56.5K-
Cormorant Asset Management, LP Boston, MA3.35MShares$63.3 Million4.17% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.94MShares$55.5 Million0.3% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.22MShares$41.9 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA2.14MShares$40.3 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.87MShares$35.2 Million0.0% of portfolio
About Longboard Pharmaceuticals, Inc.
- Ticker LBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,586,000
- Market Cap $256M
- Description
- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...